Cargando…

Correction: Hiroshi Sugano et al. Nafamostat Mesilate Enhances the Radiosensitivity and Reduces the Radiation-Induced Invasive Ability of Colorectal Cancer Cells. Cancers 2018, 10, 386

Detalles Bibliográficos
Autores principales:	Sugano, Hiroshi, Shirai, Yoshihiro, Horiuchi, Takashi, Saito, Nobuhiro, Shimada, Yohta, Eto, Ken, Uwagawa, Tadashi, Ohashi, Toya, Yanaga, Katsuhiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468731/ https://www.ncbi.nlm.nih.gov/pubmed/30857200 http://dx.doi.org/10.3390/cancers11030335

Ejemplares similares

Nafamostat Mesilate Enhances the Radiosensitivity and Reduces the Radiation-Induced Invasive Ability of Colorectal Cancer Cells
por: Sugano, Hiroshi, et al.
Publicado: (2018)

Glycogen synthase kinase‐3β activity plays a key role in the antitumor effect of nafamostat mesilate in pancreatic cancer cells
por: Haruki, Koichiro, et al.
Publicado: (2017)

Nafamostat mesilate, a nuclear factor kappa B inhibitor, enhances the antitumor action of radiotherapy on gallbladder cancer cells
por: Takada, Naoki, et al.
Publicado: (2021)

Phase II trial of nafamostat mesilate/gemcitabin/S-1 for unresectable pancreatic cancer
por: Uwagawa, Tadashi, et al.
Publicado: (2022)

Pomalidomide enhanced gemcitabine and nab-paclitaxel on pancreatic cancer both in vitro and in vivo
por: Saito, Nobuhiro, et al.
Publicado: (2018)

Cardiac arrest caused by nafamostat mesilate
por: Kim, Hyo Shik, et al.
Publicado: (2016)

Utility and safety of nafamostat mesilate for anticoagulation in dogs
por: Isayama, Noriko, et al.
Publicado: (2022)

Pomalidomide promotes chemosensitization of pancreatic cancer by inhibition of NF-κB
por: Shirai, Yoshihiro, et al.
Publicado: (2018)

Suppression of lysosomal acid alpha‐glucosidase impacts the modulation of transcription factor EB translocation in pancreatic cancer
por: Hamura, Ryoga, et al.
Publicado: (2021)

Use of Nafamostat Mesilate as an Anticoagulant during Extracorporeal Membrane Oxygenation
por: Han, Sang Jin, et al.
Publicado: (2011)

Cardiac arrest caused by nafamostat mesilate: Kounis syndrome in the dialysis room?
por: Koniari, Ioanna, et al.
Publicado: (2017)

The effect of nafamostat mesilate infusion after ERCP for post-ERCP pancreatitis
por: Kim, Joo Seong, et al.
Publicado: (2022)

Successful Nafamostat Mesilate Administration for Andexanet Alfa-Induced Heparin Resistance
por: Kitaura, Atsuhiro, et al.
Publicado: (2023)

Hiroshi Ichikawa
Publicado: (2019)

The role of nafamostat mesilate as a regional anticoagulant during extracorporeal membrane oxygenation
por: Lee, Jae Ha, et al.
Publicado: (2022)

Validation of Nafamostat Mesilate as an Anticoagulant in Extracorporeal Membrane Oxygenation: A Large-Animal Experiment
por: Han, Sung Joon, et al.
Publicado: (2018)

Nafamostat Mesilate: Can It Be Used as a Conduit Preserving Agent in Coronary Artery Bypass Surgery?
por: Yoon, Yoo Sang, et al.
Publicado: (2013)

Comparison between nafamostat mesilate and unfractionated heparin as anticoagulant during continuous renal replacement therapy
por: Makino, S, et al.
Publicado: (2015)

Nafamostat mesilate promotes endothelium-dependent vasorelaxation via the Akt-eNOS dependent pathway
por: Choi, Sujeong, et al.
Publicado: (2016)

The modulation of TRPM7 currents by nafamostat mesilate depends directly upon extracellular concentrations of divalent cations
por: Chen, Xuanmao, et al.
Publicado: (2010)

Inhibition of acid ceramidase elicits mitochondrial dysfunction and oxidative stress in pancreatic cancer cells
por: Taniai, Tomohiko, et al.
Publicado: (2021)

Nafamostat mesilate attenuates neuronal damage in a rat model of transient focal cerebral ischemia through thrombin inhibition
por: Chen, Tao, et al.
Publicado: (2014)

Nafamostat Mesilate Inhibits TNF-α-Induced Vascular Endothelial Cell Dysfunction by Inhibiting Reactive Oxygen Species Production
por: Kang, Min-Woong, et al.
Publicado: (2015)

Multicenter, single-blind, randomized controlled study of the efficacy and safety of favipiravir and nafamostat mesilate in patients with COVID-19 pneumonia
por: Ikeda, Mahoko, et al.
Publicado: (2023)

First person – Tamio Furuse and Hiroshi Mizuma
Publicado: (2019)

Nafamostat Mesilate as an Anticoagulant During Continuous Renal Replacement Therapy in Patients With High Bleeding Risk: A Randomized Clinical Trial
por: Choi, Ji-Young, et al.
Publicado: (2015)

Efficacy and safety of nafamostat mesilate anticoagulation in blood purification treatment of critically ill patients: a systematic review and meta-analysis
por: Lin, Yao, et al.
Publicado: (2022)

Nafamostat mesilate for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review and meta-analysis based on prospective, randomized, and controlled trials
por: Xie, Yu, et al.
Publicado: (2023)

Ability of Nafamostat Mesilate to Prolong Filter Patency during Continuous Renal Replacement Therapy in Patients at High Risk of Bleeding: A Randomized Controlled Study
por: Lee, Yong Kyu, et al.
Publicado: (2014)

Use of argatroban in combination with nafamostat mesilate in open-heart surgery for a pediatric patient with heparin-induced thrombocytopenia type II: a case report
por: Kawamoto, Shuji, et al.
Publicado: (2020)

The Journey of an Outstanding Scientific Mind: Prof Hiroshi Maeda (1938–2021)
por: Greish, Khaled, et al.
Publicado: (2021)

386 corales = 386 chorales /
por: Bach, Johann Sebastian, 1685-1750
Publicado: (1968)

Disease modeling and lentiviral gene transfer in patient-specific induced pluripotent stem cells from late-onset Pompe disease patient
por: Sato, Yohei, et al.
Publicado: (2015)

Continuous regional arterial infusion versus intravenous administration of the protease inhibitor nafamostat mesilate for predicted severe acute pancreatitis: a multicenter, randomized, open-label, phase 2 trial
por: Hirota, Morihisa, et al.
Publicado: (2019)

Camostat mesilate therapy for COVID-19
por: Uno, Yoshiharu
Publicado: (2020)

Radical resection of a primary unresectable duodenal cancer after chemotherapy using S-1 and cisplatin: report of a case
por: Kanehira, Masaru, et al.
Publicado: (2017)

TFEB overexpression promotes glycogen clearance of Pompe disease iPSC-derived skeletal muscle
por: Sato, Yohei, et al.
Publicado: (2016)

Metabolomic Profiling of Pompe Disease‐Induced Pluripotent Stem Cell‐Derived Cardiomyocytes Reveals That Oxidative Stress Is Associated with Cardiac and Skeletal Muscle Pathology
por: Sato, Yohei, et al.
Publicado: (2016)

Radical resection of an initially unresectable intrahepatic cholangiocarcinoma after chemotherapy with using gemcitabine, cisplatin, and S-1: report of a case
por: Tsunematsu, Masashi, et al.
Publicado: (2019)

Crystal structure of nafamostat dimesylate
por: Fujii, Isao
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_uu2qj5hf93j1rv1r0mrn2p2623